Blood pressure in early autosomal dominant polycystic kidney disease. - Wikidata - wikimedia - TriplyDB

Blood pressure in early autosomal dominant polycystic kidney disease.

Blood pressure in early autosomal dominant polycystic kidney disease.

http://www.wikidata.org/entity/Q35129320

about

Interventions for preventing the progression of autosomal dominant polycystic kidney disease Hypertension in Chronic Glomerulonephritis Combination use of medicines from two classes of renin-angiotensin system blocking agents: risk of hyperkalemia, hypotension, and impaired renal function A systematic review of the predictors of disease progression in patients with autosomal dominant polycystic kidney disease Decreased Polycystin 2 Levels Result in Non-Renal Cardiac Dysfunction with Aging The Treatment of Autosomal Dominant Polycystic Kidney Disease Stop chronic kidney disease progression: Time is approaching Identifying and integrating consumer perspectives in clinical practice guidelines on autosomal-dominant polycystic kidney disease.The importance of total kidney volume in evaluating progression of polycystic kidney disease Understanding barriers to medication, dietary, and lifestyle treatments prescribed in polycystic kidney disease Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.Angiotensin blockade in late autosomal dominant polycystic kidney disease.Rationale, design and objectives of ARegPKD, a European ARPKD registry study Molecular pathways and therapies in autosomal-dominant polycystic kidney disease Autosomal dominant polycystic kidney disease in children.Vasopressin and disruption of calcium signalling in polycystic kidney disease.Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring Experiences and Perspectives of Polycystic Kidney Disease Patients following a Diet of Reduced Osmoles, Protein, and Acid Precursors Supplemented with Water: A Qualitative Study.Anthropometric and Metabolic Risk Factors for ESRD Are Disease-Specific: Results from a Large Population-Based Cohort Study in Austria.Association of Intensive Blood Pressure Control and Kidney Disease Progression in Nondiabetic Patients With Chronic Kidney Disease: A Systematic Review and Meta-analysis.Assessing Risk of Disease Progression and Pharmacological Management of Autosomal Dominant Polycystic Kidney Disease: A Canadian Expert Consensus.Cystatin C estimated glomerular filtration rate to assess renal function in early stages of autosomal dominant polycystic kidney disease.Suppressing angiotensinogen synthesis attenuates kidney cyst formation in a Pkd1 mouse model.Automatic total kidney volume measurement on follow-up magnetic resonance images to facilitate monitoring of autosomal dominant polycystic kidney disease progression.Closeout of the HALT-PKD trials Antihypertensive treatments in adult autosomal dominant polycystic kidney disease: network meta-analysis of the randomized controlled trials.Fatty Acid Oxidation is Impaired in An Orthologous Mouse Model of Autosomal Dominant Polycystic Kidney Disease.Hypokalemic Hypertension Leading to a Diagnosis of Autosomal Dominant Polycystic Kidney Disease.Heterotrimeric G protein signaling in polycystic kidney disease Renal volume and cardiovascular risk assessment in normotensive autosomal dominant polycystic kidney disease patients Semiautomated Segmentation of Polycystic Kidneys in T2-Weighted MR Images.Incidence and survival of end-stage kidney disease due to polycystic kidney disease in Australia and New Zealand (1963-2014).7th Brazilian Guideline of Arterial Hypertension: Chapter 8 - Hypertension and Associated Clinical Conditions An association between autosomal-dominant polycystic kidney disease and the risk of acute myocardial infarction in Asian population - results of a nationwide study New options in the treatment of autosomal dominant polycystic kidney disease.The hallmarks of cancer: relevance to the pathogenesis of polycystic kidney disease.An overview of experimental and early investigational therapies for the treatment of polycystic kidney disease.Decade in review--polycystic kidney disease: Slowing progression of autosomal dominant polycystic kidney disease.Clinical Trials in Pediatric Autosomal Dominant Polycystic Kidney Disease.Performance of an Artificial Multi-observer Deep Neural Network for Fully Automated Segmentation of Polycystic Kidneys.

P2860

Q24186484-7399FDDE-BDE9-4CA6-9194-FF60073B0043 Q26768702-88C6B69B-CE23-49CC-B0EC-62AA8A52AC08 Q26795398-1A2B4B8F-C54B-46CA-AE9A-6E8D06AB70AC Q26798115-99142494-D16C-4744-A869-04E7B753D979 Q27313611-384045F3-79D1-4DD3-9DD9-626C805FE585 Q28077060-33DB1212-34DD-4205-AB87-F78060697B82 Q28078020-020AA625-7BAF-4739-A792-63011B52C11C Q30203008-80B1FF08-0617-4228-9EA0-D847EC0A14A5 Q33873107-316A38A2-418C-4BF8-9539-3AD6E45C037C Q33876797-83D0C3AB-2C76-44FD-9943-D6FE19B58579 Q34467747-288852A1-687B-47C1-B511-64E8BC5E3085 Q34836649-19411354-03BD-4838-97A9-2FF7C5D9B716 Q35176977-10878AB8-5A39-4766-B7B1-03C13F36AFB0 Q35578646-2A53984C-489A-43FD-B1E9-97CE8F9BF42C Q35596375-E69FCC6E-509D-4140-9D47-A4D80FB21084 Q35962991-C128EB49-9B90-4E28-B0C9-98AB516A50C3 Q35982717-D4F4DF5A-B876-475E-AF1F-27ED4DCE9B8F Q36106841-805A59B0-DA5B-4149-9685-48A30AD5EBE0 Q36106884-6E1A317E-302A-4AD7-9C29-B6E91F33AFB2 Q36306359-DCE866E4-C169-4C22-BD85-E9B54F9D1623 Q36315686-38E9B140-A730-4C06-B4F9-21EC14C91DFF Q36323939-81E5526B-A077-4A66-B6A1-24FC3FA95032 Q36385359-FBE1A2AE-768B-410E-963F-B90865429487 Q36497881-306734CB-B717-4598-A790-D61CC66808B8 Q36520637-8311FDEB-B7FE-46F5-96E0-F621CBF9DA7B Q36618913-AB4D583F-63E8-4CFC-8377-551C6711DA46 Q36753925-74BDC06A-72A0-497F-8EE8-7904F864CA2A Q37104447-DBDF43A7-C55B-49E0-BD35-A65754CAD38F Q37139683-9A0DE34A-71FE-4DD1-BA35-183D0C2877F3 Q37606169-05E27416-2249-4CB5-8D0C-88CCE16DB56C Q37646799-C0F0CE87-04E8-41C2-BF14-AB19713ACA60 Q37650894-961C8C6A-A679-4071-BBFD-4ED709DD863D Q37656189-84CB46D1-1416-438A-9A5C-4A4B9DCF54C6 Q37746000-C58789A1-32BC-4CB0-9505-DD9645D856E3 Q38356125-34FD8D40-C93A-4697-B114-46A0736ADAFF Q38419495-12440EE3-BED5-44C7-8255-F0260FAF7737 Q38540557-1628780F-8353-484E-A463-46520C45FBF0 Q38605692-8F628528-6258-40DD-82F9-64470DD7E6A6 Q38733796-F5566BC0-3AF4-402F-8459-2E1717D10B03 Q38760605-7A093568-C8A2-41E8-9DAD-A362CD57C887

P2860

Blood pressure in early autosomal dominant polycystic kidney disease.

http://www.wikidata.org/entity/Q35129320

description

2014 nî lūn-bûn

@nan

2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

name

Blood pressure in early autosomal dominant polycystic kidney disease.

@ast

Blood pressure in early autosomal dominant polycystic kidney disease.

@en

type

label

Blood pressure in early autosomal dominant polycystic kidney disease.

@ast

Blood pressure in early autosomal dominant polycystic kidney disease.

@en

prefLabel

Blood pressure in early autosomal dominant polycystic kidney disease.

@ast

Blood pressure in early autosomal dominant polycystic kidney disease.

@en

P1433

Q35129320-C466DB47-9F64-4E4B-8CA7-F92B0A8644C4

P1476

Q35129320-E2E1813C-AFCE-4115-963C-465BC9EFCB23

P2093

Q35129320-0021CA17-48C2-465B-8062-DAB7C6787C20

Q35129320-2349D829-F258-4A51-B8DF-5661989DA66E

Q35129320-374D97F1-BDC9-40AB-B891-9237666B2BF6

Q35129320-4782266F-67D5-416C-94FF-D7EC617D2A70

Q35129320-49E99CB2-DA23-4030-AFF1-3B527A6D330D

Q35129320-4A833D88-8B48-4959-BB20-3B1AECFB3943

Q35129320-534371E4-5165-4D49-BBF8-C42F12C34039

Q35129320-55B529E6-A3E8-46F1-97E4-1623722CF3C0

Q35129320-5E898ADB-FC86-4D20-82C7-06D54DAC580B

Q35129320-66750D48-9769-4305-8C07-59E4120AAA18

P2860

Q35129320-0DA099F8-2FAC-4188-BD9D-7CF285CBB02F

Q35129320-2A39FD2D-9387-40AA-9604-58EFA4090BBD

Q35129320-2DB32305-FC88-471A-BBC2-09575AA00C39

Q35129320-3173D294-336D-4C0D-A40F-1EF86FB4A617

Q35129320-32276CC7-8DEF-4400-ACE9-54FCC7190A6B

Q35129320-3AE295D5-ED4C-4FD0-8A98-DF0F69CA4F70

Q35129320-496CCA28-83CC-408D-A17F-DC28408D0CA3

Q35129320-4B9ECA59-0106-4E7D-965F-35AEFAB11117

Q35129320-5697DA09-C16F-4640-BA70-EB5149C63C32

Q35129320-645FF128-D358-45B2-9BBB-385771473000

P304

Q35129320-A93CAF18-DD90-4142-B36D-A6F833F06C37

P31

Q35129320-F9093A6B-3D30-4B35-9EF4-7B8F55046177

P356

Q35129320-7317EB2A-E888-4DE9-88BB-256BFD641616

P407

Q35129320-26429994-8ABA-4ED4-9921-621C41C6DB86

P433

Q35129320-FAAE7F7F-CCA2-4738-A2BF-3568D95A12FB

P478

Q35129320-B6A754BB-8BA7-4458-8DA5-AC3F22EC655F

P50

Q35129320-68D5C0B0-5190-48D1-AC21-DF934D1E3BEE

P577

Q35129320-68F080E3-2232-47A9-9B96-1C4D89DA3C5E

P5875

Q35129320-B6385F65-F7EE-4863-B259-08BFFA1FCAC9

P698

Q35129320-95B8B2C9-70A1-478F-BB70-00E58BA7EEF8

P921

Q35129320-7AE72FDC-2D53-4D60-8C8D-CF7D82754C0C

P932

Q35129320-E1A34B7B-578D-4F63-9419-BBD58B14F6AD

P356

P1433

The New England Journal of Medicine

P1476

Blood pressure in early autosomal dominant polycystic kidney disease.

@en

P2093

Arlene B Chapman

http://www.w3.org/2001/XMLSchema#string

Charity G Moore

http://www.w3.org/2001/XMLSchema#string

Dana C Miskulin

http://www.w3.org/2001/XMLSchema#string

Franz T Winklhofer

http://www.w3.org/2001/XMLSchema#string

Frederic F Rahbari-Oskoui

http://www.w3.org/2001/XMLSchema#string

Godela Brosnahan

http://www.w3.org/2001/XMLSchema#string

HALT-PKD Trial Investigators

http://www.w3.org/2001/XMLSchema#string

Jared J Grantham

http://www.w3.org/2001/XMLSchema#string

Kaleab Z Abebe

http://www.w3.org/2001/XMLSchema#string

Kyongtae T Bae

http://www.w3.org/2001/XMLSchema#string

P2860

Autosomal dominant polycystic kidney disease: the last 3 years

Random-effects models for longitudinal data

Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease.

The HALT polycystic kidney disease trials: design and implementation.

Clinical practice. Autosomal dominant polycystic kidney disease.

Improved prognosis in patients with autosomal dominant polycystic kidney disease in Denmark.

Predictors of autosomal dominant polycystic kidney disease progression

Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease.

Analysis of baseline parameters in the HALT polycystic kidney disease trials.

Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes.

P304

2255-2266

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1402685

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

371

http://www.w3.org/2001/XMLSchema#string

P50

Robert W Schrier

P577

2014-11-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

268449601

http://www.w3.org/2001/XMLSchema#string

P698

25399733

http://www.w3.org/2001/XMLSchema#string

P921

autosomal dominant polycystic kidney disease

P932

4343258

http://www.w3.org/2001/XMLSchema#string